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Purpose: To explore the associations between sleep hypoventilation (SH) and daytime arterial 
pressures of carbon dioxide (P
a
CO
2
), sleep stages, and sleep apneas/hypopneas (AHI) in subjects 
with chronic obstructive pulmonary disease (COPD). SH has previously been found in COPD-
subjects with chronic hypercapnic respiratory failure (CHRF) using supplementary oxygen 
(LTOT), and has been proposed as a possible predictor for CHRF.
Patients and methods: A prospectively designed observational study in a pulmonary rehabili-
tation hospital of 100 (39 male) stable COPD inpatients with a mean forced expiratory volume in 
1 second (FEV
1
) of 1.1 L (42% of predicted) and a mean age of 64 years, using polysomnography 
with transcutaneous measurement of carbon dioxide pressure increase (∆P
tc
CO
2
).
Results: SH as defined by the American Academy of Sleep Medicine (AASM) was found in 
15 of the subjects, seven of whom used LTOT. However, six had SH despite being normocap-
nic during the daytime (only one on LTOT). Subjects with SH had a greater ∆P
tc
CO
2
 increase 
from nonrapid eye movement (NREM) to rapid eye movement (REM) sleep stages compared 
to non-SH subjects (mean [standard deviation] between-groups difference =0.23(0.20) kPa, 
P,0.0005). Subjects with apnea/hypopnea index $15 (overlap, N=27) did not differ from those 
with COPD alone (AHI ,5, N=25) in sleep ∆P
tc
CO
2
 or daytime P
a
CO
2
. A regression model 
with the variables FEV
1
, LTOT, and sleep maximum ∆P
tc
CO
2
 explained 56% of the variance in 
daytime P
a
CO
2
 (F(3, 94) =40.37, P,0.001).
Conclusion: In stable COPD, SH as defined by the AASM was found both in normocapnic, 
non-LTOT subjects and in hypercapnic, LTOT-using subjects. Between-sleep-stage increase 
in ∆P
tc
CO
2
 was higher in subjects with SH. Overlap subjects did not differ from simple COPD 
subjects in sleep ∆P
tc
CO
2
 or daytime P
a
CO
2
.
Keywords: blood gas analysis, etiology, physiopathology, carbon dioxide, polysomnography
Introduction
Chronic obstructive pulmonary disease (COPD) has a high and increasing morbid-
ity and mortality worldwide, and is estimated to be the third leading cause of death 
by 2020.1 Chronic hypercapnic respiratory failure (CHRF) is associated with poor 
prognosis in COPD. The pathophysiological mechanisms leading to CHRF are not 
fully established, but sleep is of particular interest as a state of unstable respiration. 
Blood gas sampling during sleep is difficult, as it can interfere with sleep architecture, 
and only a few studies of small populations have been published. In COPD, end-tidal 
measurement of carbon dioxide pressure is too inaccurate to substitute for arterial 
pressure of carbon dioxide (P
a
CO
2
);3 however, transcutaneous measurement of carbon 
dioxide pressure (P
tc
CO
2
) minimally disturbs sleep, and P
tc
CO
2
 is now regarded by 
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the American Academy of Sleep Medicine (AASM) as a 
surrogate for P
a
CO
2
.4
In normal sleep, changes in central respiratory con-
trol, muscle contractility, and lung mechanics lead to 
 hypoventilation,5–7 with arterial pressure of carbon dioxide 
increasing to as much as 0.9 kPa above supine, awake 
values.8–10 In COPD this hypoventilation is more pronounced, 
especially during REM sleep, as a consequence of obstructed 
airflow, hyperinflation, respiratory muscle dysfunction, 
blunted ventilatory responses to hypercapnia and hypoxemia, 
ventilation/perfusion mismatch, and medications.11 Poor sleep 
quality is often reported, and polysomnography has shown a 
reduced total sleep time, disturbances in sleep architecture, 
and highly frequent arousals.12–15 Sleep hypoventilation was 
a common finding in two studies of stable, hypercapnic 
COPD subjects on long-term oxygen treatment (LTOT).16,17 
It is unclear whether this hypoventilation was mainly the 
result of supplementary oxygen. In COPD, daytime P
a
CO
2
 
correlates inversely with the forced expiratory volume in 
1 second (FEV
1
),18 and one study reported a more severe 
daytime hypercapnia in subjects with coexisting COPD 
and obstructive sleep apnea (overlap syndrome), compared 
to subjects with COPD or obstructive sleep apnea alone.19 
Sleep hypoventilation (SH) has recently been defined by 
the American Academy of Sleep Medicine as an increase of 
1.3 kPa or more in P
a
CO
2
 during sleep, to a value exceeding 
6.7 kPa for at least 10 minutes.4
Finding SH in normocapnic COPD subjects may be pre-
dictive of imminent hypercapnic respiratory failure, but to our 
knowledge, no studies have assessed SH in COPD subjects 
with normocapnia or in those with CHRF without LTOT.
The primary aim of this study was to determine whether 
SH is associated with daytime hypercapnia, with secondary 
aims to explore the impact of SH on the P
tc
CO
2
 increase 
between sleep stages, and whether SH or daytime P
a
CO
2
 is 
associated with the frequency of sleep apneas/hypopneas.
Material and methods
subjects
Study participants were all Caucasians and inpatients at 
the Glittreklinikken Pulmonary Rehabilitation Hospital 
from January 2010 through June 2011. Initially, 60 sub-
jects with P
a
CO
2
 ,6.3 kPa and 60 with P
a
CO
2
 $6.3 kPa, 
all with Global initiative for Chronic Obstructive Lung 
Disease (GOLD)20-defined COPD, were to be included. 
Due to fewer hypercapnic subjects, these were oversam-
pled by asking all to participate, whereas subjects with 
P
a
CO
2
 ,6.3 kPa were selected randomly, stratifying for sex 
prior to  participation request. In total, 166 subjects were 
screened for participation.
The following exclusion criteria were used: diagnosed 
obstructive sleep apnea (OSA), COPD exacerbation within 
3 weeks prior, other serious lung comorbidity (ie, cancer, 
sarcoidosis, restrictive lung disease) or diseases affecting 
thoracic or abdominal movement, unstable angina pectoris, 
hypertension, diabetes mellitus, myocardial infarction within 
last 3 months, cerebral infarction, and addiction to drugs, 
alcohol, or narcotics.
All subjects used prescribed medication, but no respira-
tory depressant drugs were taken from 48 hours prior to first 
polysomnography (PSG) recording until end of study. Sixty-
six of the 166 subjects declined, withdrew, or were excluded. 
The main reasons for decline/exclusion included fear of 
being unable to sleep with electrodes on head and body and 
technical artifacts in P
tc
CO
2
-signal (Figure 1, further details 
in Supplementary material). The remaining 100 PSGs of 
spontaneous sleep were analyzed.
The protocol was approved by the Regional Ethics 
 Committee in southeastern Norway.
Measurements
Arterial blood gas samples (PICO50, Radiometer, 
 Copenhagen, Denmark) were collected after 10 minutes 
seated rest at approximately 2 pm prior to PSG recording, and 
analyzed within 10 minutes on a Radiometer ABL720Flex 
(Radiometer). At sampling, all subjects were breathing room 
air, with the exception of those on LTOT who used their pre-
scribed dose of supplementary oxygen. Height, weight, and 
lung function tests including measurement of postbronchodi-
lator spirometry, diffusing capacity of the lung (DLCO), and 
body plethysmography of total lung  volumes (MasterScreen 
Pneumo, Jaeger-Toennies, Hoechberg, Germany) were 
recorded during first week at the hospital. Reference values 
were based on equations from the European Community for 
Coal and Steel.21 PSG data was recorded with Embla A10 
(Medcare Flaga, Reykjavik, Iceland) and P
tc
CO
2
 data with 
Tosca 500 (Radiometer, Basel, Switzerland) for two nights, 
the first night for acquaintance with the equipment, and 
N=166
invited to
participate
• 26 subjects
  declined
N=140
included
• 17 subjects
   withdrew or
   excluded due
   to acute
   illness during
   study period
N=123 PSGs
• 23 PSGs with
  technical
  artifacts
N=100
(39 male)
study
population
Figure 1 study population.
Abbreviation: Psg, polysomnography. 
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
267
sleep hypoventilation and daytime hypercapnia in stable COPD
the second night recording sleep data online to a bedside 
computer with Somnologica  Studio Version 3.3 software 
(Medcare Flaga). PSGs were only recorded on weekdays, 
with channel setup according to the 2007 recommenda-
tions from the AASM.22 When the subject went to bed, a 
nurse started the recording with the subject watching TV 
or reading to stay awake while the signal from the Tosca 
probe stabilized. After approximately 30 minutes, the nurse 
turned off the light, this time being recorded as analysis 
started for the PSG. Rise time in the morning was recorded 
by the nurse. Subjects on LTOT used their prescribed dose 
of oxygen during PSG.
The P
tc
CO
2
 data were sampled with a frequency of 
10 Hertz, with mean and maximum values calculated for 
each epoch of 30 seconds. Unpublished data collected at 
Glittreklinikken prior to the study showed equivalence 
between changes in P
tc
CO
2
 and P
a
CO
2
, but with a delay 
time of 54–57 seconds (see Supplementary material). Thus, 
P
tc
CO
2
 data were left-shifted two epochs. For each sleep stage 
in the PSG, the mean of each epoch’s mean P
tc
CO
2
 values 
were calculated, while the epoch with the highest value was 
reported as the maximum P
tc
CO
2
.
Sleep scoring was done independently by two experienced 
polysomnographists. Ten PSGs were scored by another two 
polysomnographists to select the scorer with the best con-
cordance (see Supplementary material). According to recom-
mendations from the AASM,22 a hypopnea was scored when 
nasal pressure dropped $30% for $10 seconds with $4% 
desaturation drop from baseline, with $90% of the event’s 
duration meeting the amplitude reduction criteria for hypopnea 
(criterion A).
statistical analysis
Data were assessed for normality of distribution and homo-
geneity of variance. Differences between groups were analyzed 
using Pearson chi-square test, Fisher’s exact test, Mann– 
Whitney U test, and Student’s t-test, differences within 
groups by Student’s t-test.  Relationships between groups were 
explored by chi-square tests for independence, within groups 
by Spearman’s rho and multiple regressions. No violation 
of the assumptions of normality, linearity, multicollinearity, 
and homoscedasticity was found preliminary to regression 
analysis. Concordance was measured by Cohen’s kappa. Two-
sided P-values of #0.05 were considered significant, except 
in subgroup analyses of the SH subjects (N=15), in which 
two-sided P# 0.01 was applied. All analyses were performed 
using IBM SPSS Statistics version 19 (IBM Corporation, 
Armonk, NY, USA).
Results
As shown in Table 1, the group of 24 CHRF subjects had a 
greater increase in carbon dioxide pressure (∆P
tc
CO
2
) during 
sleep compared to the normocapnic subjects, and SH by the 
AASM definition (an increase of 1.3 kPa in the P
tc
CO
2
 during 
sleep compared with awake supine level to a value exceed-
ing 6.7 kPa for at least 10 minutes) was more frequent.4 
 Likewise, they had a higher median daytime base excess 
(BE), a lower P
a
O
2
, more frequent LTOT, and they were 
older and over-represented by females. However, no differ-
ences were found in total sleep time (TST), sleep stages as 
percent of TST, awakenings, arousals, apneas, or hypopneas 
(a table of sleep parameters according to age and compared 
to normal is provided in the Supplementary material). 
Oddly, no difference was found in body mass index (BMI); 
the mean BMI was 25 kg/m2, and only 13 were obese (BMI 
$30 kg/m2), whereas 26 were underweight (BMI ,21 kg/m2). 
As would be expected, the CHRF group had more severely 
obstructed airways with hyperinflation and impaired gas 
exchange, a shorter 6-minute walking distance (6MWD), 
higher dyspnea scores (modified medical research council 
questionnaire, COPD assessment test), and a higher BMI/
obstruction/dyspnea/exercise capacity (BODE)-index.
The group of 15 SH subjects had a higher median day-
time P
a
CO
2
, and LTOT was more frequent compared to the 
non-SH group (Table 1); likewise, median BE was higher. 
No differences were found between the SH and non-SH 
groups in other medication, sex, age, BMI, smoking habit, 
spirometry, or sleep parameters mentioned above.
On average, the 15 SH subjects were severely obstructed, 
with a median (interquartile range [IQR]) FEV
1
 =0.80 (0.84) 
liters. Interestingly, however, six of the 15 SH-subjects were 
daytime normocapnic, with a median (IQR) P
a
CO
2
 of 5.00 
(0.51) kPa, and only 1 used LTOT; this subgroup had a higher 
FEV
1
 compared to the group of nine hypercapnic subjects 
(median [IQR] 1.45 (0.81) liters versus 0.63 (0.26) liters, 
P=0.002). However, BMI and sleep apneas/hypopneas (AHI) 
did not differ between the normocapnic and hypercapnic 
SH-subjects.
As illustrated in Figure 2, the median of mean ∆P
tc
CO
2
 
showed an increasing trend with deeper NREM sleep, and 
with the highest values in REM sleep, both in the non-SH 
group and in the SH group. A mean increase (standard 
deviation [SD]) from NREM to REM of 0.20 (0.16) kPa 
(P,0.001) was found in the non-SH group, whereas this 
increase was 0.46 (0.28) kPa (P,0.001) in the SH group, 
with the mean difference between the groups being 0.23 
(0.20) kPa, (P,0.0005). The pattern of gradual increase 
International Journal of COPD 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
268
holmedahl et al
T
ab
le
 1
 D
iff
er
en
ce
s 
be
tw
ee
n 
su
bj
ec
ts
 w
ith
 a
nd
 w
ith
ou
t 
C
h
r
F 
an
d 
su
bj
ec
ts
 w
ith
 a
nd
 w
ith
ou
t 
sh
; v
al
ue
s 
as
 m
ed
ia
n 
(in
te
rq
ua
rt
ile
 r
an
ge
), 
n
=1
00
N
or
m
oc
ap
ni
c 
N
=7
6a
C
H
R
F 
N
=2
4
P
N
o 
SH
  
N
=8
5
SH
  
N
=1
5
P
D
em
og
ra
ph
ic
 d
at
a
 
se
x,
 fe
m
al
e
41
 (
54
)*
20
 (
83
)*
0.
01
0
49
 (
58
)*
12
 (
80
)*
0.
10
2
 
a
ge
, y
ea
rs
64
 (
11
)
68
 (
15
)
0.
03
2
65
 (
11
)
64
 (
15
)
0.
85
4
 
BM
I, 
kg
/m
²
25
.5
 (
6.
99
)
22
.9
 (
9.
06
)
0.
19
9
24
.8
 (
6.
67
)
27
.1
 (
11
.3
)
0.
91
6
sm
ok
in
g 
ha
bi
t
 
Pa
ck
 y
ea
rs
34
 (
23
)
25
 (
18
)
0.
06
8
32
 (
22
)
31
 (
26
)
0.
78
3
 
C
ur
re
nt
 s
m
ok
er
14
 (
18
)*
2 
(8
)*
0.
34
5
14
 (
17
)*
2 
(1
3)
*
0.
67
9
sp
ir
om
et
ry
 
FV
C
, %
 o
f p
re
db
79
.5
 (
24
.3
)
57
.0
 (
21
.0
)
0.
00
0
73
.5
 (
25
)
67
.0
 (
31
.0
)
0.
84
1
 
Fe
V
1, 
%
 p
re
d
43
.0
 (
24
.8
)
25
.0
 (
11
.0
)
0.
00
0
40
.0
 (
24
.0
)
34
.0
 (
27
.0
)
0.
29
6
 
Fe
V
1/F
V
C
, r
at
io
0.
46
 (
0.
12
)
0.
37
 (
0.
09
)
0.
00
0
0.
44
 (
0.
14
)
0.
40
 (
0.
18
)
0.
18
5
 
D
lC
O
, m
m
ol
/m
in
/k
Pa
c
3.
59
 (
2.
45
)
2.
44
 (
1.
39
)
0.
00
0
3.
34
 (
2.
20
)
2.
89
 (
1.
64
)
0.
38
5
 
r
V
/T
lC
, r
at
io
d
0.
57
 (
0.
11
)
0.
72
 (
0.
12
)
0.
00
0
0.
60
 (
0.
16
)
0.
65
 (
0.
22
)
0.
29
7
M
ed
ic
at
io
n
 
lT
O
T
3 
(4
)*
12
 (
50
)*
0.
00
0
8 
(9
)*
7 
(4
7)
*
0.
00
1
 
sa
Ba
/l
a
Ba
71
 (
93
)*
24
 (
10
0)
*
0.
33
3
80
 (
94
)*
15
 (
10
0)
*
1.
00
 
T
he
op
hy
lli
ne
3 
(4
)*
1 
(4
)*
1.
00
4 
(5
)*
0 
(0
)*
1.
00
 
st
er
oi
d 
po
2 
(3
)*
3 
(1
3)
*
0.
08
8
5 
(6
)*
0 
(0
)*
1.
00
C
lin
ic
al
 d
at
a
 
C
a
T
, s
co
re
17
.0
 (
6.
0)
21
.0
 (
6.
0)
0.
00
4
18
.0
 (
7.
0)
18
.5
 (
7.
0)
0.
59
3
 
M
M
r
C
, s
co
re
2.
0 
(1
.0
)
3.
0 
(2
.0
)
0.
00
0
2.
0 
(1
.0
)
2.
0 
(2
.0
)
0.
56
1
 
6M
W
D
, m
et
er
e
46
8 
(1
73
)
29
3 
(1
10
)
0.
00
0
43
8 
(1
86
)
37
0 
(2
03
)
0.
41
9
 
BO
D
e 
in
de
xf
3.
0 
(3
.0
)
6.
0 
(2
.0
)
0.
00
0
3.
0 
(3
.0
)
6.
0 
(5
.0
)
0.
12
2
la
bo
ra
to
ry
 d
at
a
 
P a
O
2, 
kP
ag
9.
33
 (
1.
47
)
8.
23
 (
1.
84
)
0.
01
0
9.
13
 (
1.
64
)
9.
88
 (
2.
28
)
0.
16
6
 
P a
C
O
2, 
kP
a
5.
14
 (
0.
76
)
6.
83
 (
0.
68
)
–
5.
33
 (
0.
94
5)
6.
67
 (
2.
09
)
0.
01
0
 
Be
h
0.
85
 (
1.
91
)
6.
44
 (
3.
79
)
0.
00
0
1.
56
 (
2.
86
)
4.
36
 (
5.
94
)
0.
01
9
 
C
h
r
F
–
–
–
15
 (
18
)*
9 
(6
0)
*
0.
00
1
sl
ee
p 
tim
e 
an
d 
aw
ak
en
in
gs
 
T
sT
, m
in
35
2 
(7
6)
33
7 
(1
12
)
0.
21
8
34
8 
(7
7)
35
4 
(9
2)
0.
36
9
 
r
eM
%
 T
sT
21
.9
 (
7.
2)
20
.5
 (
10
.7
)
0.
36
6
21
.5
 (
7.
8)
22
.1
 (
10
.4
)
0.
91
6
 
W
a
sO
, m
in
46
 (
43
)
53
 (
10
9)
0.
46
8
50
 (
70
)
39
 (
32
)
0.
26
5
 
a
w
ak
e
24
 (
16
)
24
 (
25
)
0.
90
4
24
 (
17
)
21
 (
19
)
0.
24
5
sl
ee
p 
ar
ou
sa
ls
 
T
a
I
16
.7
 (
9.
4)
20
.2
 (
15
.7
)
0.
11
6
17
.3
 (
11
.0
)
14
.4
 (
13
.5
)
0.
46
6
 
a
a
I
1.
3 
(2
.7
)
1.
6 
(4
.0
)
0.
86
2
1.
30
 (
3.
00
)
1.
80
 (
3.
60
)
0.
88
8
 
h
a
I
2.
8 
(3
.5
)
2.
0 
(3
.2
)
0.
18
3
2.
60
 (
3.
90
)
2.
60
 (
3.
30
)
0.
71
4
sl
ee
p 
ap
ne
as
/h
yp
op
ne
as
 
a
h
I
9.
2 
(1
0.
5)
9.
6 
(1
3.
5)
0.
58
9
9.
0 
(1
0.
4)
9.
9 
(1
4.
0)
0.
99
6
 
a
h
I $
15
20
 (
26
)*
7 
(2
9)
*
0.
78
4
23
 (
27
)*
4 
(2
7)
*
1.
00
International Journal of COPD 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
269
sleep hypoventilation and daytime hypercapnia in stable COPD
with deeper sleep was not found for the median of maximum 
∆P
tc
CO
2
 (Figure 2), especially as the values in N3 sleep 
were lower compared to N2. In subjects without SH the 
N2–N3 mean ∆P
tc
CO
2
 decrease (SD) was –0.13 (0.16) kPa 
(P,0.001), whereas the SH group had a mean decrease 
of −0.36 (0.41) kPa (P=0.005); the mean difference between 
the groups was 0.35 (0.31) kPa (P=0.002).
With an AHI cutoff at 15/hour, concordance between the 
two controllers and the chosen polysomnographist was good 
(Kappa =1.00 between all three scorers, N=10, P=0.002). 
Despite exclusion of subjects with diagnosed OSA prior to 
study, only 25 subjects had AHI ,5/hour, whereas 27 had 
AHI $15/hour; the latter chosen to define overlap syndrome 
as no record of daytime sleepiness was available, while COPD 
alone was defined by AHI ,5/hour. Central and mixed apneas 
were found in 28 and 27 subjects, respectively, 4 having cen-
tral apnea/hypopnea index $1/hour (highest value 4.4/hour), 
and five having mixed apnea/hypopnea index $1/hour (high-
est value 14.1/hour). Subjects with central and mixed apneas 
were included for overlap analysis (Table 2). As expected, 
the 27 overlap subjects had a significantly lower minimum 
S
p
O
2
 compared to the 25 COPD subjects, both in REM and 
in NREM sleep. Notably, however, the overlap subjects did 
not differ from those with COPD in sleep ∆P
tc
CO
2
 or daytime 
P
a
CO
2
 (Table 2), nor in the frequency of SH (15% in COPD 
versus 16% in the overlap group, P=1.00).
Finally, as sleep hypoventilation by various definitions 
previously has been found in severe COPD with CHRF and 
LTOT,16,17 a hierarchical multiple regression was performed 
to assess whether the maximum CO
2
 increase during sleep 
(sleep max ∆P
tc
CO
2
) independently predicts daytime P
a
CO
2
 
when controlling for COPD severity (FEV
1
) and the use of 
LTOT. FEV
1
 (liters) and LTOT (yes/no) were entered at 
Step 1, explaining 52% of the variance in daytime P
a
CO
2
. 
After entry of sleep max ∆P
tc
CO
2
 (kPa) at Step 2, the total 
variance explained by the model was 56%, F(3, 94) =40.37, 
P,0.001. Thus, sleep max ∆P
tc
CO
2
 explained an additional 
4% of the variance in daytime P
a
CO
2
 after controlling 
for LTOT and FEV
1
, R square change =0.043, F change 
(1, 94) =9.24, P=0.003. In the full model, FEV
1
 recorded 
the highest beta value (−0.44, P,0.001) over LTOT (0.39, 
P,0.001) and sleep max ∆P
tc
CO
2
 (0.22, P=0.003).
Discussion
As previously shown by others, we find SH to be common 
in stable COPD subjects with CHRF using LTOT. However, 
the novelty in this study is that SH is also found in COPD  
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with CHRF without LTOT, and even in some normocapnic, 
non-LTOT subjects. We also find the mean P
tc
CO
2
  increasing 
with depth of sleep, the between-sleep-stage differences 
being greater in subjects with SH. Finally, overlap subjects 
in this study do not differ from COPD subjects in SH or in 
daytime P
a
CO
2
.
O’Donoghue et al found SH in 43% of 54 stable 
COPD subjects with CHRF, all using LTOT, when defining 
CHRF as daytime P
a
CO
2
 .6.12 kPa and SH as a ∆P
tc
CO
2
 
increase of $1.33 kPa for $20% of total sleep time.17 
Likewise,  Tarrega et al studied stable, hypercapnic COPD 
subjects on LTOT and found nocturnal hypoventilation (NHV) 
in 21% of their 80 subjects, defining NHV as an increase in 
P
a
CO
2
 .1.33 kPa in any nocturnal blood gas sample as com-
pared to the awake levels.16 Using the AASM definition, we find 
SH in 15% of our 100 subjects, and in seven of the 15 (47%) 
subjects on LTOT. Hence, this study supports O’Donoghue et al 
and Tarrega et al in the notion of SH being commonly found in 
COPD with CHRF using LTOT. Finding SH in three subjects 
with CHRF not using LTOT indicates that SH is associated with 
daytime P
a
CO
2
 independent of LTOT. However, CHRF is not 
necessary either, as SH was also found in five normocapnic, 
non-LTOT subjects.
Figure 2 illustrates the mean P
tc
CO
2
 increase with sleep 
stages, and the greater between-stages increase in subjects 
with SH versus without SH, supporting the notion that SH in 
COPD primarily is the consequence of a failing respiratory 
pump. As arterial CO
2
 increases due to hypoventilation, the 
brains’ extracellular fluid bicarbonate builds up, blunting the 
central ventilatory drive, which in turn will lead to further 
 elevation of CO
2
.23 In patients without COPD this vicious cir-
cle is broken by an arousal when P
a
CO
2
 reaches 7.3–8.7 kPa.24 
As changes in P
tc
CO
2
 are too sluggish in comparison to 
P
a
CO
2
, and in lack of a control group, this study did not 
provide data comparable to an arousal threshold. However, 
considering normal sleep maximum ∆PCO
2
 is in the range 
of 0.3–0.9 kPa,8 our findings of maximum ∆P
tc
CO
2
 values 
of 1.2–1.8 kPa (Figure 2) suggests that COPD subjects with 
SHNo SH
Median of mean ∆PtcCO2 Median of max ∆PtcCO2
0.00
0.50
1.00
1.50
Error bars: 95% CI
N0
N1
N2
N3
REM
2.00
2.50
No SH SH
0.12 0.28 0.35 0.43 0.58 0.45 0.74 0.89 0.90 1.31 0.71 0.68 0.75 0.61 0.95 1.38 1.49 1.58 1.24 1.79
Figure 2 ∆PtcCO2 according to sleep stages.
Notes: each bar represents the sleep stage median value of the mean, and alternatively the maximum ∆PtcCO2 in kPa. The first and third cluster represent the group with 
no sh; the second and fourth cluster represent the group with sh.
Abbreviations: ∆PtcCO2, increase in carbon dioxide from supine, awake rest before sleep; n0, stage n0 sleep; n1, stage n1 sleep; n2, stage n2 sleep; n3, stage n3 sleep; 
REM, rapid eye movement sleep; SH, sleep hypoventilation according to American Academy of Sleep Medicine definition.
Table 2 Blood gases in COPD and overlap subjects, as median 
(interquartile range), n=52
COPD  
AHI ,5  
N=25
Overlap  
AHI $15  
N=27
P-value
sleep
 Mean ∆PtcCO2, kPa 0.34 (0.43) 0.54 (0.29) 0.117
 Max ∆PtcCO2, kPa 0.76 (0.56) 0.94 (0.50) 0.101
 reM max ∆PtcCO2, kPa 0.86 (0.51) 1.18 (0.69) 0.210
 nreM max ∆PtcCO2, kPa 0.71 (0.59) 0.89 (0.49) 0.117
 reM min spO2, % 87.0 (7.7) 78.0 (10.0) 0.000
 nreM min spO2, % 88.5 (5.6) 83.0 (11.2) 0.001
awake
 PaO2, kPa
a 9.51 (1.92) 9.11 (1.92) 0.059
 PaCO2, kPa
a 5.36 (2.12) 5.38 (1.43) 0.880
 saO2, %
b 96.2 (3.2) 95.3 (3.4) 0.251
Notes: Prevalence of overlap could not be calculated as data on daytime sleepiness 
was not available. an=24 in COPD group; one missing from PaO2 and PaCO2, unable 
to hit artery. bn=23 in COPD group; two missing from spO2 due to technical 
problem with analysis.
Abbreviations: ahI, apnea/hypopnea Index; Max ∆PtcCO2, maximum increase in 
transcutaneous carbon dioxide pressure from supine, awake rest; Mean ∆PtcCO2, 
mean increase in transcutaneous carbon dioxide pressure from supine, awake rest; 
min spO2, minimum oxygen saturation measured by pulse oximetry; nreM, nonrapid 
eye movement sleep; reM, rapid eye movement sleep; PaCO2, arterial pressure of 
carbon dioxide; PaO2, arterial pressure of oxygen at 2:00 pm prior to sleep; saO2, 
arterial oxygen saturation; COPD, chronic obstructive pulmonary disease.
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SH have elevated CO
2
 thresholds. With the increased levels 
of ∆P
tc
CO
2
 and BE in subjects with SH, an elevated arousal 
threshold would be expected, hence unchanged frequencies 
of arousals and awakenings. Indeed, we find no significant 
differences in arousals, number of awakenings, or minutes 
of REM sleep percentage of TST between subjects with 
or without SH (Table 1). The lowest NREM ∆P
tc
CO
2
 val-
ues recorded in stage N3 both in SH and non-SH subjects 
(Figure 2) is in line with the normal hypercapnic ventilatory 
response described by Douglas et al.25
The overlap subjects do not differ from those with COPD 
alone in the frequency of SH, in sleep CO
2
-increase or in 
daytime P
a
CO
2
 (Table 2), neither are there significant dif-
ferences in AHI between subjects with SH versus without 
SH (Table 1). This can be explained by the heterogeneity 
of COPD, as both the lungs (gas exchange system) and the 
respiratory pump (ventilatory system) are affected in vari-
ous degrees of severity. Frequent apneas/hypopneas are not 
likely to result in sleep hypercapnia in patients with well-
functioning respiratory pumps, as the retained CO
2
 follow-
ing an apnea/hypopnea will be exhaled during the next few 
breaths. When scoring PSG in severely hyperinflated COPD 
patients, however, desaturation events resulting from a failing 
diaphragm can be classified as hypopneas or apneas, thus 
contributing to the AHI, even though there is no obstruction 
of the upper airways (as in OSA). In this case, one would 
expect to find AHI correlated to sleep CO
2
 increase. Hence, 
severe COPD with frequent apneas/hypopneas will be clas-
sified as overlap syndrome regardless of the etiology of the 
desaturation events.
Contrary to the findings of Resta et al,19 we did not find a 
significant difference in daytime P
a
CO
2
 in the overlap group 
as compared to the COPD group (Table 2). A main anthro-
pometric difference between the study populations is body 
weight, as Resta et al reported a mean BMI of 36 kg/m2 in 
the overlap versus 31 kg/m2 in the COPD group, while our 
subjects had a median BMI of 25 kg/m2 with no significant 
differences between overlap and COPD subjects. In a mul-
tiple regression model, Resta et al found the best predictors 
of P
a
CO
2
 in overlap subjects to be P
a
O
2
, FEV
1
, and weight, 
O’Donoghue et al found the severity of SH in COPD subjects 
best predicted by a combination of baseline P
a
CO
2
, BMI, and 
percent REM sleep,17 and Tarrega et al found NHV related 
to BMI.16 Obesity might therefore explain the discrepancy 
between the findings of Resta et al and our findings.19
The variables FEV
1
, use of LTOT, and sleep maximum 
∆P
tc
CO
2
 explain 56% of the variance in daytime P
a
CO
2
. 
A low FEV
1
 can indicate poor function of the respiratory 
pump (chronic obstruction leading to hyperinflation); LTOT 
is known to affect the central respiratory drive to breathe,26 
and increased sleep ∆P
tc
CO
2
 can indicate a blunted  respiratory 
drive as a consequence of the failing respiratory pump. 
However, the intriguing subgroup of five normocapnic, 
non-LTOT SH subjects does not fit in the picture, as they 
were not obese, nor severely obstructive or hyperinflated, 
and they had a median AHI of only 12.8/hour. Thus, their 
respiratory pump should have sufficient reserves to expel 
CO
2
 even during REM sleep.
To our knowledge, there are no previously published stud-
ies with PSG and P
tc
CO
2
 data from COPD subjects includ-
ing as many as 100 subjects. This study has its limitations, 
however. First, as previous studies indicate the prevalence of 
OSA being the same in COPD as in the normal population,27 
the study protocol did not include collection of daytime 
sleepiness data. Hence, the diagnosis of overlap syndrome 
based exclusively on the AHI is admittedly uncertain, and 
prevalence could not be analyzed. However, as OSA is 
defined either by AHI $5 and daytime sleepiness symptoms 
or AHI $15 in asymptomatic subjects,28 we chose the lat-
ter to define overlap; the most conservative criterion would 
include only certain OSA subjects in this group, whereas 
AHI ,5 was chosen to define subjects with COPD alone, 
thus reducing the risk of masking any differences between 
overlap and COPD groups.
Second, we do not regard the demographic profile in this 
study as representative for the entire COPD population in 
Norway, as a selection bias can be present for several reasons, 
including the referral/selection for lung rehabilitation, the 
oversampling of subjects with P
a
CO
2
 $6.3 kPa, and subjects 
declining to participate. As the study population had a some-
what high BODE index of 4, indicating a 4-year mortality of 
about 32%,29 the results presented does not reflect the status 
of the entire COPD population, and the prevalence of SH is 
undoubtedly lower in patients with mild COPD.
Third, as arterial blood gas samples from the subjects 
using LTOT were collected when using their prescribed 
oxygen flow, the PO
2
 and PCO
2
 referred in Table 1 do not 
reflect the untreated values of the study population. However, 
as all subjects on LTOT were stable and adapted to their 
supplementary oxygen, blood gases measured reflects their 
habitual status.
Conclusion
Sleep hypoventilation as defined by the AASM is frequently 
found in subjects with severe COPD and CHRF using supple-
mentary oxygen. The novelty of this study is the finding of SH 
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also in CHRF without LTOT, and even in some normocapnic, 
non-LTOT subjects with only moderate COPD. The carbon 
dioxide pressure increases with deeper sleep, with differences 
between sleep stages being greater in subjects with SH than 
those without SH. Subjects with AHI $15/hour (overlap) 
do not differ from those with AHI ,5 (COPD alone) in SH, 
sleep ∆P
tc
CO
2,
 or in daytime P
a
CO
2
. A regression model with 
the predictors FEV
1
, LTOT, and sleep maximum ∆P
tc
CO
2
 
explains half of the variance in daytime P
a
CO
2
.
SH is currently used in clinical practice at some centers 
as an independent indicator for the initiation of noninvasive 
positive pressure ventilation in COPD,30 and correction 
of nocturnal P
tc
CO
2
 to normocapnic values has shown to 
improve lung function and may improve survival.31,32 To 
the best of our knowledge, however, no case-control or 
prospective studies have been undertaken to investigate the 
exact mechanisms behind SH or SH’s role as a predictor for 
CHRF, so further research is clearly needed.
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Table S1 sleep parameters according to age, compared to reference populations with normal lung function, n=100
Age groups 46–59 years
Results (Reference values*) 
N=29
60–69 years
Results (Reference values*) 
N=47
70–82 years
Results (Reference valuesˆ) 
N=24
Mean SD Mean SD Mean SD
Sleep summary
TsT, min 347 (367) 56.7 (58.0) 360 (349) 54.0 (51.5) 296 (335) 56.3 (na)
awake 21 (9.7 ) 9.1 (5.2) 27 (14.6) 12 (6.7) 36 (na) 30.1 (na)
WasO, min 40 (na) 40 (na) 60 (na) 39 (na) 105 (75) 61 (na)
ses,% 90 (90) 11 (7.1) 86 (9.1) 86 (7.9) 74 (82) 15 (na
Sleep stage percentage of total sleep time
n1 13 (5.2) 6.6 (4.2) 17 (4.8) 7.1 (3.3) 21 (12) 11.7 (na)
n2 39 (63) 8.4 (17) 41 (68) 7.3 (13) 37 (56) 10 (na)
n3 26 (8.8) 9.4 (7.3) 21 (8.7) 11 (7.9) 22 (13) 12 (na)
reM 22 (23) 7.2 (7.5) 21 (19) 6.2 (8.5) 20 (19) 8.5 (na)
Notes: *reference values according to M. hirschkowitz et al9
ˆreference values according to M. Ohayon et al (adapted from graph)10 
Abbreviations: TST, total sleep time; Awake, number of awakenings; WASO, minutes wake after sleep onset; SES, sleep efficiency from sleep start; N1, stage N1 sleep; 
n2, stage n2 sleep; n3, stage n3 sleep; reM, rapid eye movement sleep; na, not available.
Supplementary material
subjects
Reasons given from the 26 subjects not participating: Anxi-
ety/fear of not being able to sleep with electrodes connected 
to head/body (ten subjects); not willing to discontinue seden-
tary medication (three subjects); fear that sleep studies would 
interfere with the rehabilitation program (three subjects); did 
not want sleep investigated (three subjects); fear of pain from 
blood gas sampling (two subjects). Two subjects declined 
because an interventional part of the project (not published) 
implied sleeping with supplementary oxygen or taking alco-
hol or zopiclone before sleep for a third polysomnography. 
One subject did not want to be seen with wires connected 
to the head, one needed to go outdoors for smoking at night 
and one did not give a reason.
Reasons for drop out of 17 subjects after initial consent 
given: Felt it impossible to sleep with wires on the body 
(seven subjects); exacerbation of COPD (six subjects); 
technical or protocol failure (two subjects); illness/disease 
of other cause (one subject); medication which excluded 
(one subject).
Twenty-three polysomnographies were excluded because 
of technical artifacts in transcutaneous measurement of 
PCO
2
; 17 because the P
tc
CO
2
 probe periodically lost contact 
with skin (low P
tc
CO
2
-signal); six because the probe was 
compressed by pillow or hand/arm (high P
tc
CO
2
-signal).
PtcCO2 versus PaCO2
The correlation between P
a
CO
2
 and P
tc
CO
2
 has been studied in 
stable subjects with lung diseases,1 in critically ill subjects,2–5 
during cardio-pulmonary exercise testing6 and in circulatory 
stable subjects; both inactive and during exercise.7,8 Con-
clusions varied as to whether P
tc
CO
2
 can substitute P
a
CO
2
. 
Hence, clinical data were obtained from 18 stable, supine 
COPD subjects with an indwelling catheter at Glittreklinik-
ken (mean FEV
1
(SD)=46(26)% of predicted, N=4 had 
P
a
CO
2
. 6.3 kPa). Every twentieth minute for up to six hours 
a pair of P
a
CO
2
 and P
tc
CO
2
 values were recorded. From 204 
pairs, a mean difference (SD) P
tc
CO
2
 – P
a
CO
2
 of 0.233 (0.312) 
kPa was found; this SD regarded as too high a variance to 
let the absolute values of P
tc
CO
2
 substitute those of P
a
CO
2
. 
However, the within subject mean difference (SD) P
tc
CO
2
 – 
P
a
CO
2
 was 0.229 (0.186) kPa. We concluded that the within 
subject SD of ,0.2 kPa indicates that the changes in P
tc
CO
2
 
can substitute the changes in P
a
CO
2
. Consequently, when 
studying COPD subjects with PSG and P
tc
CO
2
 we recorded 
the changes in P
tc
CO
2
 during sleep, not the absolute values.
PtcCO2 delay time
To find the time delay from an alveolar change in PCO
2
 
until the first response in P
tc
CO
2
, we studied nine COPD 
subjects (six male) with a mean FEV
1
(SD) of 41(20)% of 
predicted, and P
a
CO
2
, 6.3 kPa. The supine subjects wore a 
tight fitting face mask, inlet selecting either room air or a 
gas mixture of 4% CO
2
 in air. Data were collected in three 
phases, each lasting 200 sec: 1) stable phase breathing room 
air; 2) increasing phase breathing 4% CO
2;
 and 3) decreasing 
phase after switching back to room air. P
tc
CO
2
 was recorded 
every 5th second for 2 minutes, then every 10th second 
in each phase. Arterial blood samples were taken from an 
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indwelling catheter three times during phase 1), every 5th 
second the first 30 sec of phase 2) and 3), then every 30th 
second for a total of 150 seconds. The results showed a first 
response time (frt) meaning time from change in alveolar 
PCO
2
 to P
tc
CO
2
.2SD off stable phase as follows: Mean 
frt(SD) in increasing phase: 54(5,6) sec; Mean frt(SD) in 
decreasing phase: 57(15) sec. For arterial PCO
2
: 13,3(5,6) 
sec and 11,7(2,5) sec, accordingly.
sleep scoring
All PSG’s were initially scored by two independent, registered 
polysomnographists (RPSG’s) blinded to subject data except 
sex, age, height and weight. As the scorings from these two 
RPSG’s differed substantially on several sleep parameters 
(eg, AHI, HI, sleep stages) a random selection of 10 PSG’s 
were scored by another two RPSG’s who were blinded regard-
ing the results from the first two scorers. The scorings from 
the initial RPSG with the best match to the last two RPSG’s 
were then selected for data analysis.
Results, table supplement
When compared to normal subjects,9,10 the study-subjects had 
twice to threefold more awakenings and N1-sleep. However, 
they had a normal amount of REM-sleep and about twice the 
percentage of slow wave (N3) sleep (table 1).
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